Xiaobo Wang

Xiaobo Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2024 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
YZYuehan Zhou
Yuehan Zhou
JLJinzhan Lou
Jinzhan Lou
YTYuqin Tian
Yuqin Tian
JDJinlei Ding
Jinlei Ding
XWXiaobo Wang
Xiaobo Wang
BTBo Tang
Bo Tang
Tumor cells undergo metabolic reprogramming through shared pathways, resulting in a hypoxic, acidic, and highly permeable internal tumor microenvironment (TME). Lactate, once only regarded as a waste product of glycolysis, has an inseparable dual role with tumor immunity. It can not only provide a carbon source for immune cells to enhance immunity but also help the immune escape through a variety of ways. Lymphoma also depends on the proliferation signal of TME. This review focuses on the dynamic process of lactate metabolism and immune function changes in lymphoma and aims to comprehensively summarize and explore which genes, transcription factors, and pathways affect the biological changes and functions of immune cells. To deeply understand the complex and multifaceted role of lactate metabolism and immunity in lymphoma, the combination of lactate targeted therapy and classical immunotherapy will be a promising development direction in the future.

4 July 2023 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
YLYu Liu
Yu Liu
JWJinhua Wang
Jinhua Wang
XSXiaochen Shen
Xiaochen Shen
LLLi Li
Li Li
NZNing Zhang
Ning Zhang
BTBo Tang
Bo Tang

15 November 2023 in Aging
Verified
Journal Article
Open access
PDF file
ZZZhijia Zhao
Zhijia Zhao
XSXiaochen Shen
Xiaochen Shen
SZSiqi Zhao
Siqi Zhao
JWJinhua Wang
Jinhua Wang
YTYuqin Tian
Yuqin Tian
BTBo Tang
Bo Tang
Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous disease with diverse clinical and molecular features. Telomere maintenance is widely present in tumors, but there is a lack of relevant reports on the role of telomere-related genes (TRGs) in DLBCL. In this study, we used consensus clustering based on TRGs expression to identify two molecular clusters with distinct prognoses and immune cell infiltration. We developed a TRGs scoring model using univariate Cox regression and LASSO regression in the GSE10846 training cohort. DLBCL patients in the high-risk group had a worse prognosis than those in the low-risk group, as revealed by Kaplan-Meier curves. The scoring model was validated in the GSE10846 testing cohort and GSE87371 cohort, respectively. The high-risk group was characterized by elevated infiltration of activated DCs, CD56 dim natural killer cells, myeloid-derived suppressor cells, monocytes, and plasmacytoid DCs, along with reduced infiltration of activated CD4 T cells, Type 2 T helper cells, γδ T cells, NK cells, and neutrophils. Overexpression of immune checkpoints, such as PDCD1, CD274, and LAG3, was observed in the high-risk group. Furthermore, high-risk DLBCL patients exhibited increased sensitivity to bortezomib, rapamycin, AZD6244, and BMS.536924, while low-risk DLBCL patients showed sensitivity to cisplatin and ABT.263. Using RT-qPCR, we found that three protective model genes, namely TCEAL7, EPHA4, and ELOVL4, were down-regulated in DLBCL tissues compared with control tissues. In conclusion, our novel TRGs-based model has great predictive value for the prognosis of DLBCL patients and provides a promising direction for treatment optimization.

12 July 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
SZShi-Hua Zhao
Shi-Hua Zhao
ZZZunmin Zhu
Zunmin Zhu
TYTao Yang
Tao Yang
DGDa Gao
Da Gao
LLLihong Liu
Lihong Liu
WHWen-Rong Huang
Wen-Rong Huang
For primary central nervous system lymphoma (PCNSL), high-dose methotrexate (HD-MTX)-based chemotherapy remains a widely accepted induction therapy of newly diagnosed PCNSL in fit patients [1]. Despite significant advances in the treatment of PCNSL, such as cytarabine plus HD-MTX, and MATRix [2], these regimens had modest responses and a high risk of toxicities. No one regimen has been accepted as the optimal therapy. Bruton's tyrosine kinase inhibitor (BTKi)-based targeted immunochemotherapy has been recently investigated or under investigation [3, 4]; however, definite benefits are pending full results. The life-threatening toxicities (e.g., aspergillosis) with ibrutinib also limited its clinical application [5], motivating steps toward less toxic options. Orelabrutinib is an approved, second-generation BTKi with improved selectivity and persistent occupancy for BTK target, less off-target inhibition and notable blood-brain barrier permeability [6]. Previous studies have already reported encouraging signals of orelabrutinib combination in PCNSL [7]. Here, we reported the results of a prospective, multicenter, investigator-initiated, phase II study (NCT05549284) investigating the rituximab, HD-MTX plus orelabrutinib (RMO) regimen for newly diagnosed PCNSL. We enrolled patients aged 18-75 years with newly diagnosed PCNSL, no previous treatment, and ≥1 measurable lesion. Eligible patients received induction therapy with rituximab (intravenously 375 mg/m 2 on day (1), methotrexate (intravenously 3.5 g/m 2 on day (2), plus orelabrutinib (orally 150 mg once daily) every 3 weeks. Responders after the four cycles of RMO induction proceeded to protocol-specified consolidation or maintenance therapy according to tolerability and personal choice. Details on study design of this study are in Supplementary Methods. The primary endpoint was the overall response rate (ORR; complete response [CR] plus partial response [PR]) at the end of

20 December 2022 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Open access
PDF file
LZLijie Zhang
Lijie Zhang
ZWZongwei Wang
Zongwei Wang
XWXiaobo Wang
Xiaobo Wang
NZNing Zhang
Ning Zhang
JKJing Ke
Jing Ke
LYLongyan Yang
Longyan Yang
Objective: Population studies have shown that vitamin D (VitD) deficiency is associated with an increased incidence of type 2 diabetes mellitus (T2DM), VitD deficiency is a potential risk factor for T2DM, and the proportion of M1-type macrophages and M2-type macrophages in T2DM patients is imbalanced. Another study reported that VitD can affect the differentiation of macrophages into M1 and M2 types. However, there is no definitive result about the correlation between plasma VitD levels and macrophage typing in patients with T2DM. Whether VitD affects the progression of T2DM by regulating the polarization type of macrophages and the specific regulatory mechanism is not very clear. Therefore, we carried out the following research. Methods: We first used flow cytometry to detect the proportions of M1 and M2 macrophages in peripheral blood of T2DM patients with different VitD levels. Furthermore, we used ELISA to detect the inflammatory factors affecting macrophage differentiation in patients’ plasma, including IL-6 secreted by M1-type macrophages and TGF-β secreted by M2-type macrophages. Mononuclear cells were separated from human peripheral blood with immunomagnetic beads, cultured in vitro, and treated with different concentrations of VitD, and the ratio of differentiation into M1 and M2 macrophages was detected by flow cytometry. Results: With the increase of serum 25(OH)D levels in patients with T2DM, the proportion of M1 and M2 macrophages in peripheral blood decreased, that is, the polarized phenotype of macrophages was more inclined to M2 type, while plasma IL-6 gradually decreased, and TGF-β gradually increased. In addition, VitD can promote the differentiation of CD14-positive monocytes cultured in vitro into M2 macrophages. Conclusions: When the level of VitD in T2DM patients is low, there are more M1-type macrophages in peripheral blood, and when the level of VitD is increased, M2-type macrophages are increased. Changes in related inflammatory factors were also consistent. In vitro culture of monocytes further confirmed that VitD can promote the differentiation of macrophages to M2 type in T2DM patients.

10 April 2026 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
XLXiao Lu
Xiao Lu
ZSZhouying Song
Zhouying Song
CWChunhui Wang
Chunhui Wang
BPBing Pan
Bing Pan
ZXZiqi Xu
Ziqi Xu
BTBo Tang
Bo Tang
Hematologic malignancies are a group of malignant diseases originating from hematopoietic stem cells or the lymphatic system, mainly including leukemia, lymphoma, myeloma and so on. These diseases are characterized by their high heterogeneity, rapid disease progression and poor prognosis. Glycosylation is one of the most common post-translational modifications. In recent years, it has been found that abnormal glycosylation plays an important role in the genesis, development and treatment of hematologic malignancies. Aberrant glycosylation has been demonstrated to exert a significant influence on the progression of disease, impacting various biological processes including tumor cell signaling, the tumor microenvironment, cellular recognition, and immune evasion. This review synthesizes recent advances in how dysregulated glycosylation drives the biology of leukemia, lymphoma, myeloma, and other types of malignancies. Additionally, it discusses the potential value of glycosylation products that can be used as biomarkers for disease diagnosis and prognosis.